Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic
and biological information in order to optimise the therapeutic benefit relative to the …

Pharmacological treatment for chronic obstructive pulmonary disease (COPD) aims to
alleviate symptoms and reduce the future risk of events such as exacerbations, disease …

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality
worldwide; many recent advances have been made in many aspects of the disease. The aim …

Background Chronic obstructive pulmonary disease (COPD) is characterised by progressive
airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which …

The heterogeneity of chronic obstructive pulmonary disease (COPD) creates many
diagnostic, prognostic, treatment and management challenges, as the pathogenesis of …

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients
respond differently to treatment. Blood eosinophils are a potential biomarker to stratify …

Identification of a biomarker that predicts response to inhaled corticosteroids (ICS) would
help evaluate the risk/benefit profile of ICS in chronic obstructive pulmonary disease (COPD) …

Chronic obstructive pulmonary disease (COPD) is a complex condition with pathophysiology
and clinical characteristics that vary in presence and severity between patients (1). This …

Background COPD is a highly heterogeneous disease. Potential biomarkers to identify
patients with COPD who will derive the greatest benefit from inhaled corticosteroid (ICS) …

Background Treatment with systemic corticosteroids in patients with acute exacerbations of
chronic obstructive pulmonary disease (COPD) is associated with debilitating adverse …